Inspire Medical Systems (NYSE:INSP) Raised to “Strong Sell” at Barclays

Inspire Medical Systems (NYSE:INSP) was upgraded by analysts at Barclays to a “strong sell” rating in a note issued to investors on Tuesday, Zacks reports.

INSP has been the topic of several other research reports. Zacks Research cut Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 22nd. Stifel Nicolaus lifted their target price on Inspire Medical Systems from $75.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, September 11th. Royal Bank Of Canada lifted their target price on Inspire Medical Systems from $60.00 to $75.00 and gave the company a “sector perform” rating in a research report on Thursday, October 1st. Weiss Ratings upgraded Inspire Medical Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, September 22nd. Finally, Truist Financial reissued a “hold” rating and set a $62.00 price target (up from $54.00) on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have issued a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $67.29.

Inspire Medical Systems Price Performance

Inspire Medical Systems stock opened at $66.50 on Tuesday. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of 14.39, a price-to-earnings-growth ratio of 5.10 and a beta of 0.73. Inspire Medical Systems has a 1 year low of $38.91 and a 1 year high of $147.03. The firm has a 50-day moving average of $64.86 and a two-hundred day moving average of $54.06.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. The business had revenue of $200.58 million for the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company’s revenue for the quarter was down 7.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Research analysts expect that Inspire Medical Systems will post 1.24 earnings per share for the current year.

Insider Transactions at Inspire Medical Systems

In related news, insider Jason Kelly sold 963 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the transaction, the insider owned 18,985 shares of the company’s stock, valued at $1,130,556.75. The trade was a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 2.20% of the stock is currently owned by insiders.

Institutional Trading of Inspire Medical Systems

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its stake in shares of Inspire Medical Systems by 25.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,526 shares of the company’s stock worth $106,000 after purchasing an additional 305 shares during the last quarter. Valeo Financial Advisors LLC purchased a new position in Inspire Medical Systems in the third quarter valued at about $229,000. Envestnet Portfolio Solutions Inc. purchased a new position in Inspire Medical Systems in the second quarter valued at about $296,000. WINTON GROUP Ltd raised its holdings in Inspire Medical Systems by 790.8% in the second quarter. WINTON GROUP Ltd now owns 37,412 shares of the company’s stock worth $1,669,000 after purchasing an additional 33,212 shares in the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in Inspire Medical Systems in the second quarter worth about $131,000. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company focused on developing and commercializing treatments for obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is the Inspire therapy system, an implantable device designed for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefits from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses an implantable pulse generator, a stimulation lead and a sensing lead.